Aetna, part of CVS Health, will exit the individual markets in 2026, just five years after re-entering the Affordable Care Act (ACA) exchanges. Despite a return to the individual market in 2022, Aetna faced disappointing sign-ups and continued losses. CVS Health announced this decision in its Q1 earnings report, which highlighted its strategy to refocus its portfolio and improve business performance. While Aetna’s enrollment in ACA plans and Medicare declined, growth in other areas, such as commercial administrative service contracts, helped offset losses. CVS’s overall Q1 profit and revenue exceeded expectations, driven by growth in its pharmacy benefit management unit and partnerships, including one with Novo Nordisk to improve access to its GLP-1 drug Wegovy. (Article here)